The CSL Limited (ASX: CSL) share price will be on watch today following the release of its highly anticipated half year results.
What happened in the first half?
The biotherapeutics company has started FY 2020 very strongly and delivered an 11% increase in revenue to US$4,980 million in constant currency.
This was driven by an 10% increase in revenue from its CSL Behring business to US$3,768 million and a 9% lift in revenue from its Seqirus business to US$1,018 billion.
On the bottom line CSL delivered a reported net profit after tax of US$1,248 million for the six months ended December 31. This was an increase of 8%, or 11% on a constant currency basis.
The company’s chief executive officer and managing director, Paul Perreault, was pleased with the half.
He said, “I am pleased to report a strong first-half result of the 2020 financial year. Our results reflect the focused execution of our strategy, robust demand for our differentiated medicines and a deep, inherent passion for meeting the evolving needs of our patients.”
The key CSL Behring business continued its strong growth thanks to an exceptional performance by its largest franchise, the immunoglobulin portfolio.
PRIVIGEN sales grew 28% and HIZENTRA sales jumped 37% due to continued strong patient demand, together with an expanded label claim. Both products now include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a debilitating neurological disorder.
This was supported by growth in Haemophilia and Specialty sales. Haemophilia sales were up 4% thanks to strong growth in recombinant sales, whereas Specialty sales lifted 7% due partly to solid Kcentra sales growth.
As expected, Albumin sales fell 33% during the half. This was due to CSL transitioning to its new direct distribution model in China. This offset double digit growth in Europe and Emerging Markets and a 5% lift in the United States.
The Seqirus influenza vaccines business delivered another strong performance. The main drivers of its growth were a 21% lift in QIV sales and a 21% increase in Adjuvanted sales. These represent 81% of Seqirus’ total revenue.
In light of its strong first half performance, management has upgraded its profit guidance for the full year.
Mr Perreault explained: “CSL is well positioned for sustainable growth. Exceptional demand continues for our differentiated therapies. We expect to again outpace the market in expanding plasma collections and our objective to open 40 new collection centers this financial year is on track.”
CSL now expects its FY 2020 net profit after tax in the range of US$2,110 million to US$2,170 million in constant currency. This represents growth of approximately 10% to 13% growth over FY 2019 and incorporates the one-off financial impact of transitioning to a new direct distribution model in China. The company’s previous guidance was for growth of 7% to 10% in FY 2020.
The post CSL delivers strong half year result and guidance upgrade appeared first on Motley Fool Australia.
When Edward Vesely -- The Motley Fool Australia's resident dividend expert -- has a stock tip, it can pay to listen. With huge winners like Dicker Data (up 126%) and Collins Food (up 79%) under his belt, Edward is building an enviable following amongst investors that are planning for retirement.
In a brand new report, Edward has just revealed what he believes are the 3 best dividend stocks for income-hungry investors to buy now. All 3 stocks are paying growing fully franked dividends giving you the opportunity to combine capital appreciation with attractive dividend yields.
Best of all, Edward’s “Top 3 Dividend Shares To Buy For 2020” report is totally free to all Motley Fool readers.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares to buy now
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2020
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2020